Adjuvant chemotherapy for early-stage non-small cell lung cancer

The past, the present and the future

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Complete resection is mandatory in order to achieve a cure in patients with early-stage non-small cell lung cancer (NSCLC). However, despite complete resection, a substantial proportion of patients have disease recurrence, with distant metastases being the primary sites of failure. Recent trials have conclusively demonstrated the benefit of platinum-based adjuvant therapy in patients with resected stage IB and II NSCLC. The role of adjuvant chemotherapy in resected stage III NSCLC is less clear, with trials showing conflicting results. The role of targeted agents in this setting is being investigated. Gene expression profiling studies should help direct chemotherapy to those who would actually benefit from it, thereby saving others from unnecessary toxicity.

Original languageEnglish (US)
Pages (from-to)709-716
Number of pages8
JournalExpert Opinion on Biological Therapy
Volume6
Issue number7
DOIs
StatePublished - Jul 1 2006

Fingerprint

Chemotherapy
Adjuvant Chemotherapy
Non-Small Cell Lung Carcinoma
Cells
Platinum
Gene expression
Toxicity
Gene Expression Profiling
Neoplasm Metastasis
Recurrence
Drug Therapy
Therapeutics

Keywords

  • Adjuvant
  • Early stage
  • Lung cancer
  • Outcome
  • Therapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Adjuvant chemotherapy for early-stage non-small cell lung cancer : The past, the present and the future. / Potti, Anil; Ganti, Apar Kishor P.

In: Expert Opinion on Biological Therapy, Vol. 6, No. 7, 01.07.2006, p. 709-716.

Research output: Contribution to journalReview article

@article{a2b19f780e5745a4a58741046c891a10,
title = "Adjuvant chemotherapy for early-stage non-small cell lung cancer: The past, the present and the future",
abstract = "Complete resection is mandatory in order to achieve a cure in patients with early-stage non-small cell lung cancer (NSCLC). However, despite complete resection, a substantial proportion of patients have disease recurrence, with distant metastases being the primary sites of failure. Recent trials have conclusively demonstrated the benefit of platinum-based adjuvant therapy in patients with resected stage IB and II NSCLC. The role of adjuvant chemotherapy in resected stage III NSCLC is less clear, with trials showing conflicting results. The role of targeted agents in this setting is being investigated. Gene expression profiling studies should help direct chemotherapy to those who would actually benefit from it, thereby saving others from unnecessary toxicity.",
keywords = "Adjuvant, Early stage, Lung cancer, Outcome, Therapy",
author = "Anil Potti and Ganti, {Apar Kishor P}",
year = "2006",
month = "7",
day = "1",
doi = "10.1517/14712598.6.7.709",
language = "English (US)",
volume = "6",
pages = "709--716",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Elsevier BV",
number = "7",

}

TY - JOUR

T1 - Adjuvant chemotherapy for early-stage non-small cell lung cancer

T2 - The past, the present and the future

AU - Potti, Anil

AU - Ganti, Apar Kishor P

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Complete resection is mandatory in order to achieve a cure in patients with early-stage non-small cell lung cancer (NSCLC). However, despite complete resection, a substantial proportion of patients have disease recurrence, with distant metastases being the primary sites of failure. Recent trials have conclusively demonstrated the benefit of platinum-based adjuvant therapy in patients with resected stage IB and II NSCLC. The role of adjuvant chemotherapy in resected stage III NSCLC is less clear, with trials showing conflicting results. The role of targeted agents in this setting is being investigated. Gene expression profiling studies should help direct chemotherapy to those who would actually benefit from it, thereby saving others from unnecessary toxicity.

AB - Complete resection is mandatory in order to achieve a cure in patients with early-stage non-small cell lung cancer (NSCLC). However, despite complete resection, a substantial proportion of patients have disease recurrence, with distant metastases being the primary sites of failure. Recent trials have conclusively demonstrated the benefit of platinum-based adjuvant therapy in patients with resected stage IB and II NSCLC. The role of adjuvant chemotherapy in resected stage III NSCLC is less clear, with trials showing conflicting results. The role of targeted agents in this setting is being investigated. Gene expression profiling studies should help direct chemotherapy to those who would actually benefit from it, thereby saving others from unnecessary toxicity.

KW - Adjuvant

KW - Early stage

KW - Lung cancer

KW - Outcome

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33746049470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746049470&partnerID=8YFLogxK

U2 - 10.1517/14712598.6.7.709

DO - 10.1517/14712598.6.7.709

M3 - Review article

VL - 6

SP - 709

EP - 716

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 7

ER -